MAGE-A8 Overexpression in Transitional Cell Carcinoma of the Bladder: Identification of Two Tumour-associated Antigen Peptides

Overview

Journal Br J Cancer

Specialty Oncology

Date 2004 Jun 24

PMID 15213716

Citations 7

Authors

E Bar-Haim

A Paz

A Machlenkin

D Hazzan

B Tirosh

L Carmon

B Brenner

E Vadai

O Mor

A Stein

F A Lemonnier

E Tzehoval

L Eisenbach

Affiliations

Soon will be listed here.

Abstract

Bladder carcinoma is the fourth most common cancer in men and the eighth most common cancer among women. Our study is aimed to characterise tumour-associated antigen peptides of transitional cell carcinoma of the bladder (TCC). A DNA micro-array-based differential display analysis of 10 000 genes was carried out, and MAGE-A8 gene expression was detected in the tumour, and not in the normal bladder. High occurrence of MAGE-A8 expression was observed in fresh tumour samples (17 out of 23) and TCC lines (four of eight). The MAGE-A8 protein sequence was screened for HLA-A2.1-binding motifs, six potential peptides were synthesised, and peptides binding to HLA-A2.1 were assured. Immunogenicity and antigenicity of the MAGE-A8 peptides were examined in the HHD system, murine class I MHC knockout mice, transgenic for HLA-A2.1. The MAGE-A8 peptide immunogenicity was examined in three modes of vaccination, delivered intranasally with cholera toxin, injected into the tail base with complete Freund's adjuvant (CFA), or presented directly as loaded onto cell surface HLA-A2.1 molecules. Two peptides, 8.1 and 8.3, induce CTL that kills the T24 TCC line in vitro, and prime human lymphocyte response of healthy donors. These results demonstrate the potential use of the MAGE-A8 peptides for specific immunotherapy of TCC.

Citing Articles

Expression of MAGE A1 to MAGE A10 in the Forceps Biopsy and Bronchoalveolar Lavage Specimens from Patients with the Central Lung Tumor.

Mastutik G, Rahniayu A, Marhana I, Amin M, Ruslan S, Trianto H Asian Pac J Cancer Prev. 2024; 25(1):159-167.

PMID: 38285780 PMC: 10911746. DOI: 10.31557/APJCP.2024.25.1.159.

Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.

Verma S, Swain D, Kushwaha P, Brahmbhatt S, Gupta K, Sundi D Cancers (Basel). 2024; 16(2).

PMID: 38254738 PMC: 10813664. DOI: 10.3390/cancers16020246.

T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors.

Tsimberidou A, Van Morris K, Vo H, Eck S, Lin Y, Rivas J J Hematol Oncol. 2021; 14(1):102.

PMID: 34193217 PMC: 8243554. DOI: 10.1186/s13045-021-01115-0.

Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder.

Afsharpad M, Nowroozi M, Mobasheri M, Ayati M, Nekoohesh L, Saffari M Pathol Oncol Res. 2017; 25(1):191-199.

PMID: 29058301 DOI: 10.1007/s12253-017-0313-4.

'1-8 interferon inducible gene family': putative colon carcinoma-associated antigens.

Tirosh B, Daniel-Carmi V, Carmon L, Paz A, Lugassy G, Vadai E Br J Cancer. 2007; 97(12):1655-63.

PMID: 18071348 PMC: 2360281. DOI: 10.1038/sj.bjc.6604061.

References

Lucas S, Brasseur F, Boon T . A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. Cancer Res. 1999; 59(16):4100-3. View

Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K . Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res. 2001; 7(1):23-31. View

Gueguen M, Patard J, Gaugler B, Brasseur F, Renauld J, Van Cangh P . An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol. 1998; 160(12):6188-94. View

Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L . CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature. 1994; 369(6475):67-71. DOI: 10.1038/369067a0. View

Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S, Makuuchi M . Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer. 1999; 85(6):1234-40. View

Porgador A, Staats H, Faiola B, Gilboa E, Palker T . Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol. 1997; 158(2):834-41. View

Schena M, Shalon D, Heller R, Chai A, Brown P, Davis R . Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A. 1996; 93(20):10614-9. PMC: 38202. DOI: 10.1073/pnas.93.20.10614. View

Heidecker L, Brasseur F, Probst-Kepper M, Gueguen M, Boon T, Van den Eynde B . Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J Immunol. 2000; 164(11):6041-5. DOI: 10.4049/jimmunol.164.11.6041. View

Pascolo S, Bervas N, Ure J, Smith A, Lemonnier F, Perarnau B . HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med. 1997; 185(12):2043-51. PMC: 2196346. DOI: 10.1084/jem.185.12.2043. View

10.

Nseyo U, Lamm D . Immunotherapy of bladder cancer. Semin Surg Oncol. 1997; 13(5):342-9. DOI: 10.1002/(sici)1098-2388(199709/10)13:5<342::aid-ssu8>3.0.co;2-d. View

11.

Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S . An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001; 61(14):5544-51. View

12.

Cox A, Skipper J, Chen Y, Henderson R, Darrow T, Shabanowitz J . Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 1994; 264(5159):716-9. DOI: 10.1126/science.7513441. View

13.

Pascolo S, Schirle M, Guckel B, Dumrese T, Stumm S, Kayser S . A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res. 2001; 61(10):4072-7. View

14.

Kawakami Y, Eliyahu S, Delgado C, Robbins P, Sakaguchi K, Appella E . Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994; 91(14):6458-62. PMC: 44221. DOI: 10.1073/pnas.91.14.6458. View

15.

Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman L . Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med. 1997; 185(5):833-41. PMC: 2196170. DOI: 10.1084/jem.185.5.833. View

16.

THURNER B, Roder C, DIECKMANN D, Heuer M, Kruse M, Glaser A . Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999; 223(1):1-15. DOI: 10.1016/s0022-1759(98)00208-7. View

17.

De Plaen E, Arden K, Traversari C, Gaforio J, Szikora J, De Smet C . Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 1994; 40(5):360-9. DOI: 10.1007/BF01246677. View

18.

Yewdell J . Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol. 2001; 11(7):294-7. DOI: 10.1016/s0962-8924(01)02030-x. View

19.

Patton S, Craig Hall M, Ozen H . Bladder cancer. Curr Opin Oncol. 2002; 14(3):265-72. DOI: 10.1097/00001622-200205000-00003. View

20.

Colella T, Bullock T, Russell L, MULLINS D, Overwijk W, Luckey C . Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med. 2000; 191(7):1221-32. PMC: 2193167. DOI: 10.1084/jem.191.7.1221. View